Navigation Links
Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Date:2/11/2008

dition, Anesiva is pursuing corporate partnerships for the registration and commercialization of Zingo outside the licensed territories, and in support of the development and commercialization of Adlea for multiple potential indications.

Conference Call Details

Anesiva will conduct a webcast conference call with the investment community at 4:30 p.m. EDT, today, February 11, 2008 to discuss its financial results and to review the company's progress and future outlook. Interested parties can listen to the live conference call by dialing 800-340-6289 (international dial: 706-634-1538) or by logging on to http://www.anesiva.com and going to the Investor Information page. For those unable to participate via the Internet, a replay will be available for seven days after the call by dialing 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 31729950. The webcast will be available until the company's next quarterly financial results conference call.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, a
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Anesiva Appoints Daniel Janney to Board of Directors
2. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
3. Anesiva Announces Completion of Common Stock Offering
4. Anesiva Raises $45 Million in Common Stock Offering
5. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
6. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
7. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... SAN ANTONIO , 23 de julio de ... ADBI (ADBI o la Compañía) ha anunciado hoy ... Akron (ABIA o el Instituto), ... de ADBI, un dispositivo de terapia de señal ...   El Instituto, que tiene una ...
(Date:7/23/2014)... , July 23, 2014 ... portfolio company of Trendlines Agtech , announced ... Israel,s leading agricultural thermoplastics ... Valentis,s technology combines nanocrystalline cellulose (NCC), ... waste, with additional nanoparticles to produce highly improved ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber Inc. ... company producing sustainable chemicals, today announced that the underwriters ... their option to purchase an additional 420,000 shares ... of $12.00 per share, less underwriting discounts and ... public offering of 2,800,000 shares of common stock, ...
(Date:7/23/2014)... Shire plc (LSE: SHP, ... biopharmaceutical company, and ArmaGen, a US privately held ... collaboration agreement for AGT-182, an investigational enzyme replacement ... the central nervous system (CNS) and somatic manifestations ... collaboration strengthens Shire,s rare disease pipeline of innovative ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... Mass., March 11 Abt Associates announced it has ... United States Agency for International Development (USAID) to lead ... while protecting biodiversity in Mexico.Mexico is a member of ... 2000 mile border with the United States. USAID ...
... Pharma, Inc. (NYSE Alternext US: DDD) today reported financial ... 31, 2008. The Company will host a live ... (Eastern Daylight Time)."Last year was an important period for ... Ph.D., M.B.A. "Utilizing our unique CDT(R) platforms, we made ...
... State of Qatar to Introduce State-of-the-Art Treatments including ... the leading cancer centers in the Middle East ... Medical Systems (NYSE: VAR ) equipped ... Al Amal Hospital in Doha, Qatar, is replacing ...
Cached Biology Technology:USAID Selects Abt Associates to Lead Team in Strengthening Mexico Private Sector Competitiveness 2SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 2SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 3SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 4SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 5SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 6SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 7SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 8Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 2Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 3
(Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
(Date:7/23/2014)... hookworms and a protist called Blastocystis can be ... argues we should rethink our views of organisms that live ... co-author Julius Luke even ingested three developmental stages of a ... more than a year with the tapeworms, which might have ... now, he says he feels fine. , "I knew there ...
(Date:7/23/2014)... YORK, NY -- The New York Stem Cell Foundation ... to develop stem cell resources to investigate and explore ... Batten disease, a fatal illness affecting children. , NYSCF ... from skin samples of young people affected by juvenile ... cell lines are produced by artificially "turning back the ...
Breaking Biology News(10 mins):MedNet Appoints Clareece West As Chief Operating Officer 2Intestinal parasites are 'old friends,' researchers argue 2Intestinal parasites are 'old friends,' researchers argue 3NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease 2NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease 3
... in the United States will receive a diagnosis of breast ... cause of cancer-related death in women. Now a new test ... patient. "Our research shows that there is a subset ... at all, other than a lumpectomy," explains Philip Bernard, M.D., ...
... free, two-day colloquium begins February 12, 2009 with the ... originator of the modern theory of evolution of species ... foundation of all modern biology. The invited speakers provide ... and empirical research. As such, the symposium emphasizes how ...
... direct chemical modifications to specific sites on recombinant proteins ... pharmaceutical industry has been developed by Carolyn Bertozzi ... Lawrence Berkeley National Laboratory and the University of California ... diabetes, can be made in bacterial systems like ...
Cached Biology News:New test for breast cancer will help guide treatment choices 2Darwin's legacy in 21st century biology 2Tailor-made recombinant proteins in mammals 2Tailor-made recombinant proteins in mammals 3Tailor-made recombinant proteins in mammals 4
... Phosphothioate (PTO) oligonucleotides: PTOs are ... the phosphate backbone is replaced by a ... against nuclease degradation. PTOs are available as ... are phosphothioates Oligonucleotides with thio-caps ...
The mini vertical flow workbench is designed to perform PCR protocols in a particle-free environment. The built-in UV light ensures the elimination of any nucleic acid to avoid cross-contamination....
... For microsatellite research, the 4300 System ... genotyping automation software available. SagaGT automates electrophoresis, ... band sizes, and allele scoring. ,Saga GT ... LI-COR. Saga 1.0 (Unix) was initially developed ...
MOUSE ANTI GTP BINDING PROTEIN...
Biology Products: